Related Experiment Videos
Population pharmacokinetics of gentamicin in premature infants
M Izquierdo1, J M Lanao, L Cervero
1Department of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of Salamanca, Spain.
Insights
Gentamicin dosing in newborns requires careful consideration of gestational age and weight for optimal clearance and distribution. Adjusting administration intervals can prevent accumulation, especially in premature infants, due to gentamicin
Area of Science:
- Pharmacology
- Neonatal Medicine
- Clinical Pharmacy
Background:
- Gentamicin is a crucial antibiotic for treating neonatal infections.
- Accurate dosing is vital due to narrow therapeutic windows and potential toxicity.
- Understanding population pharmacokinetics in neonates is essential for safe and effective use.
Purpose of the Study:
- To characterize the population pharmacokinetics of gentamicin in a diverse newborn cohort.
- To identify key demographic predictors influencing gentamicin's pharmacokinetic parameters.
- To optimize gentamicin dosing strategies for improved therapeutic outcomes in neonates.
Main Methods:
- Population pharmacokinetic analysis using a single-compartment model.
- Inclusion of 97 newborn patients with varying gestational and postnatal ages.
- Multiple linear regression to assess demographic variable impact on clearance and volume of distribution.
Main Results:
- Gestational age emerged as the strongest predictor for gentamicin clearance and optimal daily dose.
- Postconceptional age improved predictive capacity in premature infants.
- Weight significantly predicted apparent distribution volume across the newborn population.
Conclusions:
- Gestational age and postconceptional age are critical for tailoring gentamicin therapy in neonates.
- Increased dosing intervals are recommended to prevent drug accumulation, particularly in premature infants.
- Individualized gentamicin dosing based on patient-specific factors ensures therapeutic efficacy and minimizes toxicity.
Abstract:
The population kinetics of gentamicin were studied in 97 newborn patients with a gestational age ranging between 28 and 43 weeks and a postnatal age ranging between 2 and 30 days undergoing routine therapeutic monitoring of their serum gentamicin levels. The individual kinetic analysis of serum drug levels was performed using a single-compartment model. The clearance and apparent distribution volume were calculated in each patient. The population model employed assumes the existence of residual variability in the serum concentrations and interindividual variability in the pharmacokinetic parameters. The effects of demographic variables on the clearance, distribution volume, and optimum daily dose of gentamicin were established using multiple linear regression. Gestational age is the best predictive variable of the clearance and the optimum dose/day in the whole population studied. In the premature infant patients, the predictive capacity increases with postconceptional age. Weight is a good predictive variable of all of the parameters, especially of the apparent distribution volume in the overall population of newborns. Analysis of the population kinetic behavior and optimum dose/day in each subgroup recommends that the interval of drug administration should be increased, keeping the same dose/day ratio, due to the tendency of the drug to accumulate its long half-life, especially in premature babies.